Abstract
Objectives: Although nivolumab plus ipilimumab has become a standard treatment regimen for metastatic clear cell renal cell carcinoma (ccRCC), its eff......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
